TY - JOUR
T1 - Effects of Tau and MAP2 on the Interaction of Maytansine with Tubulin
T2 - Inhibitory Effect of Maytansine on Vinblastine-Induced Aggregation of Tubulin
AU - Fellous, A.
AU - Ludueña, R. F.
AU - Prasad, V.
AU - Jordan, M. A.
AU - Anderson, W.
AU - Ohayon, R.
AU - Smith, P. T.
PY - 1985/10/1
Y1 - 1985/10/1
N2 - Maytansine, a potent inhibitor of mitosis and in vitro microtubule assembly, was used to demonstrate a striking difference in the mechanism by which two of the main groups of brain microtubule-associated proteins, Tau and MAP2, interact with tubulin. At the low concentrations of 0.5 to 2 μM, maytansine inhibited Tau-catalyzed tubulin assembly more effectively than it did MAPrcatalyzed assembly. This effect differed markedly from that of vinblastine, although both drugs bind competitively to tubulin. At the same low concentrations, vinblastine almost completely inhibited Tau- and MAP2-mediated tubulin assembly. At higher concentrations of 10 to 40 μ M, a more striking difference was observed between the actions of the two drugs. Maytansine very effectively inhibited tubulin assembly promoted by either Tau or MAP2. Vinblastine also had this effect on MAP2-mediated tubulin assembly but in the presence of Tau induced extensive tubulin aggregation into spirals. In addition maytansine strongly inhibited vinblastine-induced Tau-dependent tubulin aggregation into spiral polymers. Even at very low concentrations, maytansine completely inhibited the effect of very high concentrations of vinblastine. These results very strongly suggest that the binding sites of maytansine and vinblastine on the tubulin molecule overlap and that the changes that they probably induce in the conformation of this molecule are markedly different, at least in the presence of microtubule-associated proteins.
AB - Maytansine, a potent inhibitor of mitosis and in vitro microtubule assembly, was used to demonstrate a striking difference in the mechanism by which two of the main groups of brain microtubule-associated proteins, Tau and MAP2, interact with tubulin. At the low concentrations of 0.5 to 2 μM, maytansine inhibited Tau-catalyzed tubulin assembly more effectively than it did MAPrcatalyzed assembly. This effect differed markedly from that of vinblastine, although both drugs bind competitively to tubulin. At the same low concentrations, vinblastine almost completely inhibited Tau- and MAP2-mediated tubulin assembly. At higher concentrations of 10 to 40 μ M, a more striking difference was observed between the actions of the two drugs. Maytansine very effectively inhibited tubulin assembly promoted by either Tau or MAP2. Vinblastine also had this effect on MAP2-mediated tubulin assembly but in the presence of Tau induced extensive tubulin aggregation into spirals. In addition maytansine strongly inhibited vinblastine-induced Tau-dependent tubulin aggregation into spiral polymers. Even at very low concentrations, maytansine completely inhibited the effect of very high concentrations of vinblastine. These results very strongly suggest that the binding sites of maytansine and vinblastine on the tubulin molecule overlap and that the changes that they probably induce in the conformation of this molecule are markedly different, at least in the presence of microtubule-associated proteins.
UR - http://www.scopus.com/inward/record.url?scp=0022273836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022273836&partnerID=8YFLogxK
M3 - Article
C2 - 3928146
AN - SCOPUS:0022273836
SN - 0008-5472
VL - 45
SP - 5004
EP - 5010
JO - Cancer Research
JF - Cancer Research
IS - 10
ER -